Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Weight Gain During HIV Treatment and the Latest in HIV Prevention

March 8-11, 2020; Boston, Massachusetts
Hear insights from Monica Gandhi, MD, MPH, on new data reported at CROI 2020 related to weight gain and other metabolic changes during HIV antiretroviral therapy (ART) as well as new information on HIV prevention strategies.
Monica Gandhi, MD, MPH
Released: June 5, 2020

Podcast Notes

In this episode, Dr. Gandhi discusses topline results from several studies investigating weight gain and metabolic outcomes with different antiretroviral therapy (ART) regimens among patients with HIV, including lipid level changes, cardiovascular disease risk, diabetes risk, and metabolic syndrome risk. The overview will include analyses from:

  • The ADVANCE trial comparing initial ART with DTG plus FTC/TAF, DTG plus FTC/TDF, or EFV/FTC/TDF, including an examination of the influence of CYP2B6 polymorphisms on weight change during EFV-based therapy
  • The NA-ACCORD study
    • Evaluating patients with virologic suppression who switched from non–integrase inhibitor (INSTI)–based regimens to INSTI-based regimens
    • Investigating the impact of initial ART regimen class on diabetes mellitus incidence
  • A study investigating the association between resting metabolic rate, oxygen consumption, and dietary intake changes and body weight/composition changes following ART initiation
  • A study evaluating differences in postpartum weight change with DTG-based vs EFV-based ART

In addition, Dr. Gandhi reviews new information on biomedical prevention of HIV infection, including results from several preclinical trials, a study investigating real-time urine-based testing for tenofovir levels, and the latest safety data from the phase III DISCOVER trial comparing FTC/TDF vs FTC/TAF for daily oral HIV pre-exposure prophylaxis (PrEP) among cis-gender men who have sex with men (MSM) and transgender women.

Content based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.

Link to full program: https://www.clinicaloptions.com/hiv/conference-coverage/retroviruses-2020

Information on this Educational Activity


Monica Gandhi, MD, MPH

Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco
Medical Director
Ward 86 HIV Clinic
San Francisco General Hospital
San Francisco, California

Monica Gandhi, MD, MPH, has no relevant conflicts of interest to report.


Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Related Content

Slides from Dr John Baxter and Clinical Care Options (CCO): Proviral genotyping may help to inform ART choice in experienced patients who are suppressed

John D. Baxter, MD Released: January 24, 2022

Slides from Dr John Baxter and Clinical Care Options (CCO): Transmitted drug resistance does not necessarily preclude the use of many first line ART options.

John D. Baxter, MD Released: January 24, 2022

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for older patients with renal impairment or liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: January 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings